Phase II Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Albumin-Bound Paclitaxel and Lenvatinib as Second-Line Therapy for Unresectable or Metastatic Biliary Tract Cancer
Clinical trial NCT07530445 · RECRUITING
Trial details
- NCT number
- NCT07530445
- Sponsor
- Sun Yat-sen University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-03-23
- Primary completion
- 2027-04-30
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.